BioCentury | Sep 13, 2019
Finance

After single exit, Avalon seeks path forward for build-to-buy assets from GSK deal

...The last of the four, Iron Horse Therapeutics, has an intrathecally delivered small molecule targeting EPHA4...
...is investing its 2015-vintage eleventh fund, which closed with about $120 million. Targets: EPHA4 - EPH receptor A4...
BioCentury | Apr 12, 2019
Clinical News

Merrimack discontinues last clinical candidate

Merrimack discontinued development of MM-310 -- the company's last remaining product in clinical testing -- after a safety update showed that a Phase I trial in solid tumor patients "would not be able to reach...
BioCentury | Jun 29, 2018
Clinical News

Merrimack discontinues pancreatic cancer candidate after Phase II miss

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) reported that first-line treatment with istiratumab (MM-141) missed the primary and secondary endpoints in the Phase II CARRIE trial to treat metastatic pancreatic cancer. The company said it will discontinue the...
BioCentury | Jun 25, 2018
Clinical News

Merrimack falls on Phase II pancreatic cancer failure

Merrimack Pharmaceuticals Inc. (NASDAQ:MACK) lost $4.01 (44%) to $5.14 on Monday after reporting that first-line treatment with istiratumab (MM-141) missed the primary and secondary endpoints in the Phase II CARRIE trial to treat metastatic pancreatic...
BioCentury | Mar 13, 2018
Distillery Therapeutics

Cancer

INDICATION: Breast cancer Studies in mice suggest a peptide-based EPHA2 agonist conjugated to paclitaxel could help treat triple-negative breast cancer (TNBC). Conjugation of an EPHA2 agonist peptide to the generic chemotherapy paclitaxel and in vitro...
BioCentury | Dec 22, 2017
Clinical News

Stemline reports additional Phase II data for SL-701 in GBM

In November, Stemline Therapeutics Inc. (NASDAQ:STML) reported additional data from the two-stage Phase II STML-701-0114 trial of SL-701 as a second-line treatment of glioblastoma multiforme (GBM). Data were presented at the Society of Neuro-Oncology meeting...
BioCentury | Nov 15, 2017
Distillery Therapeutics

Neurology

...correlated with low levels of EPHA4-SORL1 interactions. In cortical neurons from mice, SORL1 overexpression decreased EPHA4...
...interactions. In cortical neurons from mice, SORL1 overexpression decreased EPHA4 activation whereas SORL1 knockout increased EPHA4...
...steps include identifying compounds that enhance SORL1-EPHA4 interactions. TARGET/MARKER/PATHWAY: Sortilin-related receptor 1 (SORL1; gp250; LR11); EPH receptor A4 (EPHA4)...
BioCentury | Nov 8, 2017
Preclinical News

Team identifies new role for SORL1 in Alzheimer's disease

...current study, the researchers showed that the protein acts downstream of beta amyloid by modulating EPH receptor A4 (EPHA4)...
...expression, while SORL1 knockout increased EPHA4 expression in neurons. Biochemical assays showed SORL1 interacts with EPHA4...
...and found an inverse correlation between elevated EPHA4 levels and the association of SORL1 with EPHA4...
BioCentury | Aug 17, 2017
Finance

Built to purpose

...Calporta Therapeutics Inc. is targeting TRPML1 for lysosomal storage disorders; Iron Horse Therapeutics is targeting EPHA4...
...CDH1 (CD324) - E-cadherin CGRP - Calcitonin gene-related peptide ENPP2 (ATX) - Autotaxin EPHA4 - EPH receptor A4...
BioCentury | Jun 9, 2017
Finance

Pedaling to the clinic

With lead candidate BT-1718 expected to enter the clinic this year, Bicycle Therapeutics Ltd. has padded its coffers with a £40 million ($51.3 million) series B to expand its pipeline of bicyclic peptides for cancer....
Items per page:
1 - 10 of 62